Moleculin Biotech (MBRX)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 04 Apr 2018 15:41

Moleculin Announces Patients Treated In FDA Approved Phase I/Ii Annamycin Clinical Trial
14:33 (04/04) - Bron: RTRS
April 4 (Reuters) - Moleculin Biotech Inc :
* MOLECULIN ANNOUNCES PATIENTS TREATED IN FDA APPROVED PHASE
I/II
ANNAMYCIN CLINICAL TRIAL
Munnybunny liked last!
be the reason someone smiles today. or the reason they drink. whatever works


Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 04 Apr 2018 17:43

alles kan beter schreef:Moleculin Announces Patients Treated In FDA Approved Phase I/Ii Annamycin Clinical Trial
14:33 (04/04) - Bron: RTRS
April 4 (Reuters) - Moleculin Biotech Inc :
* MOLECULIN ANNOUNCES PATIENTS TREATED IN FDA APPROVED PHASE
I/II
ANNAMYCIN CLINICAL TRIAL


Yep een update

Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
HOUSTON, TX--(Marketwired - April 04, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that patients have successfully begun treatment in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML").
The first patient enrolled in Moleculin's Annamycin clinical trial was treated at The University Hospitals Cleveland Medical Center Seidman Cancer Center on March 28, 2018.

"It is exciting to now have this trial fully under way," commented Walter Klemp, Chairman and CEO of Moleculin. "We are also pleased that the same Cancer Center has begun treatment of the second patient as well, so we are hopeful that the pace of recruitment will also meet our expectations. We continue to work toward opening additional U.S. sites to increase patients' access to this clinical trial."
lode78 liked last!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 12 Apr 2018 06:22

RESALE BY SELLING SHAREHOLDERS OF UP TO 2.1 MILLION SHARES
OF
CO'S COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS
be the reason someone smiles today. or the reason they drink. whatever works

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: MOLECULIN BIOTECH INC

Berichtdoor alles kan beter » 24 Apr 2018 17:23

MOLECULIN ENTERS AGREEMENT WITH BSP PHARMACEUTICALS FOR
ITS
LEUKEMIA DRUG CANDIDATE
* MOLECULIN BIOTECH INC - ENGAGED BSP PHARMACEUTICALS
S.P.A. TO
BEGIN PREPARATIONS FOR COMMERCIAL SCALE PRODUCTION OF ANNAMYCIN
DRUG PRODUCT
be the reason someone smiles today. or the reason they drink. whatever works

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 24 Apr 2018 17:24

MOLECULIN ENTERS AGREEMENT WITH BSP PHARMACEUTICALS FOR
ITS
LEUKEMIA DRUG CANDIDATE
* MOLECULIN BIOTECH INC - ENGAGED BSP PHARMACEUTICALS
S.P.A. TO
BEGIN PREPARATIONS FOR COMMERCIAL SCALE PRODUCTION OF ANNAMYCIN
DRUG PRODUCT
be the reason someone smiles today. or the reason they drink. whatever works

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 03 Mei 2018 11:53

Begint beweging in te komen. Benieuwd of het door $2 kan breken.
alles kan beter liked last!

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 03 Mei 2018 19:36

Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial

HOUSTON, May 03, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has engaged Voisin Consulting Life Sciences (“VCLS”), as an additional regulatory consulting firm and contract research organization (“CRO”) to prepare for expansion of its clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).

Moleculin engaged Voisin Consulting Life Sciences, headquartered in Paris, France to evaluate additional countries for the potential expansion of its AML clinical trial. VCLS is a multinational regulatory consulting firm and contract research organization with 150 life science professionals. The Moleculin engagement is intended to evaluate Australia and selected Western European countries to provide additional clinical sites.

“Now that our AML trial is underway, we are focused on expanding the opportunity for AML patients to participate in the trial,” commented Walter Klemp, Moleculin’s Chairman and CEO. “Our strategy is to choose countries with the best possible balance between an efficient clinical trial authorization process, solid AML clinical trial experience and a population of qualified AML patients.”

About Voisin Consulting Life Sciences

From discovery to product launch and life cycle management

AT Voisin Consulting Life Sciences (VCLS), regulatory science guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. Starting early in the process, from discovery to patient, VCLS assists innovators in designing optimized product development plans and regulatory strategies, combining the health ecosystem with commercial success. With a presence in seven locations across three continents and over 150 employees, VCLS serves a broad range of developers and their investors.

For more information, visit http://www.voisinconsulting.com
alles kan beter liked last!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 05 Jun 2018 07:53

On Friday, shares in Houston, Texas headquartered Moleculin Biotech Inc. recorded a trading volume of 48,798 shares. The stock ended the session 0.59% lower at $1.68. The Company's shares have gained 88.76% in the past twelve months. The stock is trading below its 50-day moving average by 8.26%. Moreover, shares of Moleculin Biotech, which focuses on the development of oncology drug candidates, have a Relative Strength Index (RSI) of 39.68. Get the full research report on MBRX for free by clicking below at:
http://www.wallstequities.com/registration/?symbol=MBRX
be the reason someone smiles today. or the reason they drink. whatever works

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 573
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 203
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 12 Jun 2018 13:46

MOLECULIN TARGETS ACCELERATED FDA APPROVAL OF WP1732 PURSUES DEVELOPMENT FOR OCULAR TUMORS
be the reason someone smiles today. or the reason they drink. whatever works

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 12 Jun 2018 17:28

Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors


June 12, 2018 07:30 ET | Source: Moleculin Biotech, Inc.
HOUSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement with the Jagiellonian University in Krakow, Poland, for the development of its STAT3 inhibitor, WP1732, for the treatment of ocular tumors.

“Today there are very limited options for the treatment of ocular tumors," commented Walter Klemp, Chairman and CEO of Moleculin. “And, these tumors are believed to involve a significant upregulation of the activated form of STAT3. It is important to note that, in addition to the ability of WP1732 to inhibit the proliferation and survival of cancer cells in preclinical studies, as STAT3 inhibitor, it is designed to potently block cancer stem cells and induce immune system function to overcome tumor-induced immune tolerance. This could make WP1732 an ideal candidate for targeting these unique and highly metastatic tumors.”

Mr. Klemp continued: “We remain committed to targeting accelerated approval pathways for WP1732 by focusing on significant unmet needs. This includes niche indications like ocular tumors and AML, as well as high-profile indications like pancreatic cancer.”
alles kan beter liked last!